CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (124,323)	$ (65,165)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,604	3,701
Amortization of right-of-use operating lease assets	2,395	602
Amortization of other assets	607	592
Amortization of premium (discount) on investments, net	(5,042)	4,175
Amortization of debt issuance costs	1,486	1,343
Non-cash interest related to sale of future royalties	15,363	0
Stock-based compensation expense	26,948	26,236
Loss (gain) on investments	529	(10)
Non-cash losses related to disposal of property, plant and equipment	0	527
Non-cash losses related to other assets	445	110
Changes in operating assets and liabilities:
Contracts receivable	11,624	35,774
Inventories	(167)	774
Other current and long-term assets	5,312	(7,222)
Income taxes payable	11,037	865
Accounts payable	(10,295)	2,878
Accrued compensation	(31,018)	(22,285)
Accrued liabilities and other current liabilities	(28,460)	10,473
Deferred contract revenue	(13,037)	(25,018)
Net cash used in operating activities	(133,992)	(31,650)
Investing activities:
Purchases of short-term investments	(688,278)	(462,855)
Proceeds from sale of short-term investments	374,363	178,837
Purchases of property, plant and equipment	(10,472)	(2,705)
Acquisition of licenses and other assets, net	(1,253)	(826)
Net cash used in investing activities	(325,640)	(287,549)
Financing activities:
Proceeds from equity, net	2,560	1,848
Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options	0	(9,173)
Proceeds from sale of future royalties	500,000	0
Payments of transaction costs related to sale of future royalties	(10,434)	0
Principal payments on mortgage debt	(39)	0
Net cash provided by (used in) financing activities	492,087	(7,325)
Effects of exchange rates on cash	104	(154)
Net increase (decrease) in cash and cash equivalents	32,559	(326,678)
Cash and cash equivalents at beginning of period	276,472	869,191
Cash and cash equivalents at end of period	309,031	542,513
Supplemental disclosures of cash flow information:
Interest paid	89	594
Income taxes paid	293	2
Supplemental disclosures of non-cash investing and financing activities:
Amounts accrued for capital and patent expenditures	$ 3,058	$ 1,344